101 related articles for article (PubMed ID: 11522757)
1. Tumor genomics vs. tumor genetics: a paradigm shift?
Meltzer SJ
Gastroenterology; 2001 Sep; 121(3):726-9. PubMed ID: 11522757
[No Abstract] [Full Text] [Related]
2. The Molecular Biologic Basis of Esophageal and Gastric Cancers.
Pennathur A; Godfrey TE; Luketich JD
Surg Clin North Am; 2019 Jun; 99(3):403-418. PubMed ID: 31047032
[TBL] [Abstract][Full Text] [Related]
3. "OMICS" technologies and their role in foregut primary malignancies.
Farid SG; Morris-Stiff G
Curr Probl Surg; 2015 Oct; 52(10):409-41. PubMed ID: 26527526
[No Abstract] [Full Text] [Related]
4. Prognostic value of hypoxia-regulated gene expression in loco-regional gastroesophageal cancer.
Winther M; Alsner J; Tramm T; Holtved E; Baeksgaard L; Nordsmark M
Acta Oncol; 2016 May; 55(5):652-5. PubMed ID: 26623712
[No Abstract] [Full Text] [Related]
5. Next-generation Sequencing in the Management of Gastric and Esophageal Cancers.
Rubinstein JC; Nicolson NG; Ahuja N
Surg Clin North Am; 2019 Jun; 99(3):511-527. PubMed ID: 31047039
[TBL] [Abstract][Full Text] [Related]
6. Gene amplification in gastric and esophageal adenocarcinomas.
Houldsworth J; Cordon-Cardo C; Ladanyi M; Kelsen DP; Chaganti RS
Cancer Res; 1990 Oct; 50(19):6417-22. PubMed ID: 2400999
[TBL] [Abstract][Full Text] [Related]
7. [Tumors of upper digestive tract].
Sasaki H; Aoyagi K; Minashi K; Fukagawa T; Katai H
Nihon Rinsho; 2010 Aug; 68 Suppl 8():444-50. PubMed ID: 20976921
[No Abstract] [Full Text] [Related]
8. The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis.
Fassan M; Pizzi M; Realdon S; Balistreri M; Guzzardo V; Zagonel V; Castoro C; Mastracci L; Farinati F; Nitti D; Zaninotto G; Rugge M
Hum Pathol; 2013 Sep; 44(9):1804-10. PubMed ID: 23618359
[TBL] [Abstract][Full Text] [Related]
9. Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: from pathology to treatment.
Maresch J; Schoppmann SF; Thallinger CM; Zielinski CC; Hejna M
Crit Rev Oncol Hematol; 2012 Jun; 82(3):310-22. PubMed ID: 21783379
[TBL] [Abstract][Full Text] [Related]
10. Ectopic expression of guanylyl cyclase C in adenocarcinomas of the esophagus and stomach.
Park J; Schulz S; Haaf J; Kairys JC; Waldman SA
Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):739-44. PubMed ID: 12163327
[TBL] [Abstract][Full Text] [Related]
11. Alterations of the CCND1 and HER-2/neu (ERBB2) proteins in esophageal and gastric cancers.
Bizari L; Borim AA; Leite KR; Gonçalves Fde T; Cury PM; Tajara EH; Silva AE
Cancer Genet Cytogenet; 2006 Feb; 165(1):41-50. PubMed ID: 16490596
[TBL] [Abstract][Full Text] [Related]
12. Cytokeratin expression patterns in noncardia, intestinal metaplasia-associated gastric adenocarcinoma: implication for the evaluation of intestinal metaplasia and tumors at the esophagogastric junction.
Shen B; Ormsby AH; Shen C; Dumot JA; Shao YW; Bevins CL; Gramlich TL
Cancer; 2002 Feb; 94(3):820-31. PubMed ID: 11857318
[TBL] [Abstract][Full Text] [Related]
13. Morphological analysis of gastro-esophageal diseases by molecular cell techniques.
Jankowski J; Henderson K; Viaene A; Baert J; Long LQ
Microsc Res Tech; 1995 Jun; 31(3):184-92. PubMed ID: 7670158
[TBL] [Abstract][Full Text] [Related]
14. MET signaling pathway: a rational target for cancer therapy.
Appleman LJ
J Clin Oncol; 2011 Dec; 29(36):4837-8. PubMed ID: 22042966
[No Abstract] [Full Text] [Related]
15. Allelic deletion in 11p15 is a common occurrence in esophageal and gastric adenocarcinoma.
Moskaluk CA; Rumpel CA
Cancer; 1998 Jul; 83(2):232-9. PubMed ID: 9669804
[TBL] [Abstract][Full Text] [Related]
16. Expression profile of malignant and nonmalignant lesions of esophagus and stomach: differential activity of functional modules related to inflammation and lipid metabolism.
Gomes LI; Esteves GH; Carvalho AF; Cristo EB; Hirata R; Martins WK; Marques SM; Camargo LP; Brentani H; Pelosof A; Zitron C; Sallum RA; Montagnini A; Soares FA; Neves EJ; Reis LF
Cancer Res; 2005 Aug; 65(16):7127-36. PubMed ID: 16103062
[TBL] [Abstract][Full Text] [Related]
17. Cofactor of BRCA1: a novel transcription factor regulator in upper gastrointestinal adenocarcinomas.
McChesney PA; Aiyar SE; Lee OJ; Zaika A; Moskaluk C; Li R; El-Rifai W
Cancer Res; 2006 Feb; 66(3):1346-53. PubMed ID: 16452188
[TBL] [Abstract][Full Text] [Related]
18. HER2 positivity in gastric and esophageal adenocarcinoma: clinicopathological analysis and comparison.
Koopman T; Smits MM; Louwen M; Hage M; Boot H; Imholz AL
J Cancer Res Clin Oncol; 2015 Aug; 141(8):1343-51. PubMed ID: 25544671
[TBL] [Abstract][Full Text] [Related]
19. Involvement of cancer-activating genes on chromosomes 7 and 8 in esophageal (Barrett's) and gastric cardia adenocarcinoma.
Vissers KJ; Riegman PH; Alers JC; Tilanus HW; van Dekken H
Anticancer Res; 2001; 21(6A):3813-20. PubMed ID: 11911252
[TBL] [Abstract][Full Text] [Related]
20. Fibroblast growth factor receptor 2 expression, but not its genetic amplification, is associated with tumor growth and worse survival in esophagogastric junction adenocarcinoma.
Tokunaga R; Imamura Y; Nakamura K; Ishimoto T; Nakagawa S; Miyake K; Nakaji Y; Tsuda Y; Iwatsuki M; Baba Y; Sakamoto Y; Miyamoto Y; Saeki H; Yoshida N; Oki E; Watanabe M; Oda Y; Bass AJ; Maehara Y; Baba H
Oncotarget; 2016 Apr; 7(15):19748-61. PubMed ID: 26933914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
